Successful Inspections -Before, During and After

Maurice Makdessi & Gaye Camm Manufacturing Quality Branch Department of Health and Aged Care, TGA



GMP FORUM 2024



tga.gov.au

Agenda

- Types of inspections
- Importance of GMP inspections
- GMP Code & Coverage
- Inspection preparation and process
- Expectation at Inspection
- Effective close out
- Cases
- Q&A



Initial inspection

- Variation inspections
- Routine re-inspections
- Compliance inspections

Both domestic and overseas manufacture for the Australian market

Initial inspection

A new manufacturing site in Australia or the first time TGA inspects an overseas manufacturing site

Purpose

To assess the GMP compliance of the facility, quality system and processes for issuing a licence or certificate

How to be successful

Engage early, understand application and inspection timeframes for effective planning.





- Initial inspection
- Variation inspections
- Routine re-inspections
- Compliance inspections

Both domestic and overseas manufacture for the Australian market

Variation inspection

A variation inspection assesses the ability of a manufacturing site to undertake a new process

Purpose

To allow licensed sites in Australia to vary their manufacturing licences

How to be successful

Engage early, understand application and inspection timeframes for effective planning.

- Initial inspection
- Variation inspections
- Routine re-inspections
- Compliance inspections

Both domestic and overseas manufacture for the Australian market

Routine re-inspection

A risk based inspection program of licensed sites and overseas sites supplying Australia.

Purpose

Ongoing assessment of the GMP compliance of manufacturing sites.

How to be successful

Be inspection ready. Maintain your QMS and corrective and preventative actions.

- Initial inspection
- Variation inspections
- Routine re-inspections
- Compliance inspections

Both domestic and overseas manufacture for the Australian market

Compliance inspection

An inspection triggered by information received by the TGA to determine possible enforcement actions.

Purpose

To assess a compliance signal at either licensed sites or overseas sites supplying Australia

How to be successful

Be transparent, provide requested information and explain your processes to show how your systems are GMP compliant

Effective application of GMP Level of compliance Marketing Authorisation verification

Additional reasons we may plan an inspection of a manufacturer:

- Review the effective close out of CAPAs
- Follow-up after product recall
- Examine specific quality issues
- Collect evidence in an unannounced inspection

Verify effective application of GMP

Effective Pharmaceutical Quality System (PQS)

- Facility
- Systems
- Processes
- Equipment
- People
- Product quality control

Ability to investigate effectively & evaluate impacts

Ability to follow documented procedures

Ability to assess risks & control potential impacts

- New product introduction
- Equipment changes
- New technology or software introduction
- Deviation & non-conforming product or processes
- Validations & qualifications

Marketing Authorisation

The approval given to supply a therapeutic good in Australia and, in most cases, involves entry on the Australian Register of Therapeutic Goods (ARTG).

Applies to:

- Domestically manufactured therapeutic goods approved, or unapproved, for supply in Australia
- Therapeutic goods imported into, or exported from, Australia

Marketing Authorisation

Australian Register of Therapeutic Goods (ARTG)

When market authorisation is granted, the product is added to an **electronic register** of therapeutic goods.

The ARTG details

- Information such as the product name, dosage form, therapeutic type, product category
- All sites of manufacturer involved in bringing the product to its finished state
- Formulation including actives and excipients
- Packaging presentation (AUSTR only)
- The ARTG entry is usually under the sponsor's name

Department of Health and Aged Care

41		3.0	1	4.3	1.0.1	2
IDCD	(QCI)	0C (4)	XXQ3	-60	TITISTE	901

	ARTG#	Product name							
Record Summary									
liponeor									
Therapeutic Type	Medicine								
Product Category	Registered								
RTO Start Date	30/10/2020								
Postal Address	37.13373								
Billing Address									
Product Type									
Gratia	Medicine	Registered							
	Allve								
Approval Area	Crug sarety	creation creato							
Donditiona									
Conditions applicable to Section 20 of the There	all therapeutic good peutic Goods Act 19	a as specified in the	e document " 1995,	Standard Conditiona /	Applying	g to Registered	or Listed Th	empeutic Go	ods Unde
							12-17-22	1000	
Conditions applicable to	the relevant category	v and class of the	apeutic poods	as specified in the d	toourner	# "Standard Co	Indiacine Acc	siving to Reg	stand of
Sonditions applicable to Jated Therapeutic Goor	the relevant categor is Under Section 28	y and class of the of the Therapeutic	Goods Act 15	as specified in the d	tocument 1995	t "Standard Co	onditions App	stying to Reg	to beredal
Conditions applicable to Jated Therapeutic Good rocks	the relevant categor to Under Section 28	y and class of the of the Therapeutic	apeutic prode Goods Act 15	as specified in the d Roy' effective 1 July 1 Ro	iocument 1995	t "Standard Cr br supply	inditions App	sying to Reg	to beredai
Conditions applicable to Jated Therapeutic Goo recor	the relevant categor Is Under Section 28	y and class of the of the Therapeutic	apeutic poots Goods Act 15	nan specified in the d MAP affective 1 July 1 R	locumen 1995. albase f	nt "Standard Cr for supply	nations App	oying to Reg	idered or
Conditions applicable to Jated Therapeutic Goo Incor Dominiants	the relevant categor to Under Section 28	y and class of the of the Therapeutic	npeutic goods Goods Act 15	nas specified in the d MS* affective 1 July 1 R	locumen 1965 alease f	t "Standard Cr for supply g and labelling	ndtona App	stying to Reg	intered or
Conditions applicable to Jarled Thempeutic Goo locor Comments WWW Description	the relevant categor to Under Section 26 Tec	y and class of the of the Therapeutic	npeutic goods Goods Act 19	n as specified in the d MO ^P effective 1 July 1 R R R Th Th	locument 1995 laikase f laikaginy leating bi	t "Standard Ci for supply g and labelling integration	enditions App	Nying to Reg	no benedar
Control on a policiade to Juned Therapeutic Goor rocci Comments WWY Description Kothcaton of Change	the relevant categor to Under Section 28 Tec	y and class of the of the Therapeutic	upeutic goods Goods Act 15	is specified in the d Mor effective 1 July 1 Re Th Re Mor	alease for entropy to entropy to entropy to entropy to entropy to	t "Standard Cr for supply g and labelling iological or supply ure of dosace i	unditions App	Nying to Reg	n bereda
Control on a policide to Linted Therapeutic Goor rocce Comments WWW Description Kotfloation of Change Reconstructs	the relevant sategor Is Under Section 28	y and class of the of the Therapeutic	npeutic goods Goods Act 15	is specified in the d SO ² effective 1 July 1 Pr Th Th Th Th Th Th Th Th Th Th Th Th Th	ackaging ackaging bi alease fo lanufacti asting ci	t "Standard Cr for supply g and labelling introjical or supply une of dosage t termical and ph	um ysical	ayerg to Reg	idened of
Conditions applicable to Jener Therspectic Goo rocco Domments WW Description Kostication of Change Rendecturens	the relevant sategor to Linder Section 20 Tec	y and class of the of the Therapeutic	npeutic goods Goods Act 15	naa specified in the d Allo ⁿ effective 1 July 1 R R R R R R R R R R R R R R R R R R R	adaging adaging adaging bi alagse fo alagse fo	n Yotandard Co for supply g and labelling islogical or supply cos of doarge t ternical and ph artity	um yeitai	aying to Reg	ident or
Conditions applicable to inter Therapeutic Goo coor Comments Minn Searchpfion Sostication of Change Ranufacturers Satz#	the relevant categor to Linder Section 20 Tec Address	y and class of the of the Therapeutic	npeutic goods Goods Act 15	in a specified in the d digit affective 1 July 1 R R Tr R R Tr Tr Tr Tr	ackinging acking to alkase for alkase for al	t "Standard Co br supply g and labelling locigical or supply use of docage i bernical and ph artiby cture of API	um yeital	aying to Reg	idend of
Conditions applicable to intern Therapeutic Good according Second Contraction Second Cont	the relevant categor de Linder Section 28 Tec Address	y and class of the of the Therapeutic	apauli: goodi Gooda Act 15	no gostini pred Alexandro I July R R R R R R R R R R R R R R R R R R R	socument 1995 silease f adapting bi silease fo lanufact eating of eating of manufact manufact	tr Yotandard Co for supply g and labelling kological or supply une of doarge t herrical and ph setting ture of API y peckaging	bern yeitael	nymg to Reg	idered of
Conditions applicative to Internet Transport Coord Coo	the relevant categor to Under Section 28 Tex Address	y and class of the of the Therapeutic	apauli: goods Goods Act 15	n an apactified in the d BAP effective 1 July R R R R R R R R R R R R R R R R R R R	lactures adding for eating to eating to eating of eating of eating of eating of eating of eating of	e Whandard Co br supply g and labelling islogical or supply une of doasge to benesial and ph solity tare of API y peckaging	kenn yelaal	aying to Reg	idensi pr
Contens applicate to and Therepeats Goo coord With Description Association of Change Recordschares Base Products 1. Product nam	the relevant categor to Under Section 38 Tex Address	y and class of the	apeufic goods Goods Act 15	n an aparthet in the d BAR affective 1 July R R R R R R R R R R R R R R R R R R R	Socurrent 1995 a Base 1 a Gaginy asting to alasting of asting at manufact asting at manufact	tr Yosandard Cu br supply g and labelling istigical or supply use of doarge t hemical and ph artitly dare of API y peckaging	um yekal	nywg 15 Reg	idered or
Sondharn spokale to and Thenpedic Goo coord Sonorests WW Beschption Resultation of Change Resultation of Change Resultations Resultatio	the relevant categor to Under Section 20 Tex Address E Single Medicine P	y and class of the of the Therapeutic t	apade goods Goods Act 19	n an good filled in the day and the second state of the second second second second second second second second second second second second second second se	boomen 1995 alisten f adiagon alisten fo alisten fo ali	end labeling gand labeling should be upply or supply to supply tarse of doage in terminal and ph antity tarse of A/Pi y peckaging	Lum yetaal	9999 15 Reg	idered of
Sondharn spokale to and Therepeak Goo coord Sonorests WW Seachption Seachptio	the relevant categor to Under Section 20 Text Address B Single Medicine P	y and class of the of the Thangeutic	apadis goods Goods Act 19	n an good field in the day and the second state of the second second second second second second second second second second second second second second sec	Socurrent 1995 Inisates f Inisates fo Inisates fo Inis	In Youndard Cu for supply g and labeling location or supply an of dosage i series and physics of the series of API tartity tars of API tartity Current Science 2 a - 50	torm yelcal	999 11 Reg	at the second se
Contern applicate to and Thanpack Goo coord Second Contents Manufactures Manufactur	the relevant categor to Under Sector 20 Tex Address Single Medicine P s	y and class of the of the Thampeutic t	apada post	an a postibuli in teo d allor effective i durg Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr Pr	Socurrent 1995 Inisiates f Inisiates fo Inisiates fo Inis	In Youndard Cu for supply g and labeling isological or supply one of dosage herical and ph anity dure of API y peckaging Current 500/2023 9:50	um yekal	9,99,915 R4g	
Contern applicate to and Therepedic Goo coord Minimum Description Association of Change Resultation of Change Resultation of Change Resultations Moducts 1. Product nam Product Type Permitted Indication	the relevant categor to Under Section 30 Text Address 6 Single Madicine P e min Induded on Reco	y and class of the of the Thanspeulic f	specific goods Goods Act 15	n an good field in the display of the second	Socurren 1985 Indesting Indesting to Indesting of International Internat	In Youndard Cu br supply g and labelling location or supply use of docate entropy to satisfy docate of API y peckaging Current Science2 ar50	tem yekal	9,99,99,15,84g	to benefit
Sondhern applicate to and Therepeak Goo coord Sonorests WW Secolption Resultation of Change Resultation of Change Resultation Resultation Product Type Product Type Permitted Indication In Promoted Indication	the relevant categor to Under Section 20 Tec Address E Single Medicine P e min Induction of Reco	y and class of the of the Thangeutic	ngeudie goods Goods Aut 15	n an operative filt for the display of the filt of the	Sourren 1985 Ribase f Ribase f Isrufact Ribase f Ribase f	In Youndard Cu for supply g and labelling location or supply and dynamic for supply and dynamic for supply supply supply supply ture of API y peckaging Current Sciences arts	tern yelaal	9,99,15 R4g	
Contens applicate to come applicate to come c	the relevant categor to Under Section 20 Tex Address Single Medicine P e not Industed on Rece ents metric industed on Rec	y and class of the of the Thampeutic t	apacife goods Goods Act 19	an a postibuli in teo di alla di addicione i dalla di Ri Ri Ri Ri Ri Ri Ri Ri Ri Ri Ri Ri Ri	Source 1995 In Adres 1 Indiana 1 Ind	nt "Bendend Cu br supply gend labeling lebgical or supply territorial and ph antity tarrest and ph antity y peckaging Current Science 222 9:50	Lem yekal	9,99,10 Reg	
Contern applicate to contern applicate to contern applicate to contern applicate to contern applicate to contern application of charge familiaria of charge familiaria of contern application familiaria application familiariaria familiaria familia	the relevant categor to Under Section 30 Text Address 6 Single Medicine P e mail Industed on Reco write mentio Industed on R	y and cleas of the of the Thampeutic f	apacife goods Goods Act 15	n an good field in the d and of affective 1 days i Principal Principal Principal Status Effective Date	Sourner 1995 Initiate f Initiate	et Vaenderd Cu br supply g end labelling kinglical er supply source of Anny et hermoal and ph anithy dame of API y peckaging Current Science2 arts	torm yelical	9,99,10 Reg	
Sondhern applicate to and Thenpests Goo coord WWW Beschption Isofficialish of Change Renufactures Base Products 1 . Product nam Product Type Permitted indication No Permitted indicate No Standard Indication No Standard Indication	the relevant categor to Under Section 20 Tex- Address E Single Medicine P a main Industed on Reco ants main Industed on Reco	roduct	agaudie goods Goods Act 19	n an operative filte to the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the state of the sta	Sourner Initiate f Initiate f Ini	e Mandard Cu br supply g and labelling kitigital or supply theread and ph avitay tame of Appl heread and ph avitay to a Appl theread and ph avitay y peckaging Current Science2 arts	torn gelaal		
Sondhern applicate to and Therapeutic Goo coord Sonorents WWW Seachption Seachption Seachption Seachption Seachption Seachption Seachption Seachption Seachption Seachption Seachption Standards Register No Parolluct Indication Register Standard Indication Standard Indication Standard Indication Seacht Indication Register Standard Indication	the relevant categor to Under Section 20 Text Address Bingle Medicine P Single Medicine P e marks Inducted on Reco ants metab Inducted on Reco	y and class of the of the Thampeutic t notuct accord	agaudie goods Goods Act 15	e as good field in the deal of a field of the second second field of the second second second second field second second second second second field second s	Sourner Initiate f Initiate f Ini	nt "Stendard Cu br supply g and labeling kitigital or supply territorial and ph antity tarre of API territorial and ph antity tarre of API territorial and ph antity territorial antity territorial ant	tern gelaat	9,99,15 Reg	

Record Summary

The details contained in this copy of the Record Summary reflect the information held at the nominated date and time of printing The currency and accuracy of the details can be confirmed at www.ebs.goi.au.

Guide to Good Manufacturing Practice for Medicinal Products - version 16 (PE009-16)

- The design and elements of a Pharmaceutical Quality System
- Facility and equipment design and suitability
- Product manufacture, packaging, labelled, storage and release
- Quality control testing, including on-going stability
- Consistency of processes via validation& qualification
- Cleaning effectiveness and measure to minimise cross contamination risks
- Environmental monitoring
- Equipment maintenance & calibration
- Suitability of staff and effective training measures

Inspection process

• Preparation

- Conduct
- Post inspection and closure

Inspector preparation

- Scheduling of inspection manufacturer contacted
- Announcement of the inspection via letter detailing agreed dates
- Document requests to assist in inspection preparation
- Review of TGA files compliance issues to follow up, previous inspection issues, CAPA from previous inspections requiring verification
- Search for any recall events since last inspection
- Prepare the inspection plan in accordance with the information received

Preparing for a successful inspection

Manufacturer preparation

- Scheduling \rightarrow ensure site contact information in eBS is correct
- Announcement → alert inspector if key personnel will be unavailable or no production is planned during the inspection
- Pre-inspection document requests → ensure documents accurately reflect the site & activities conducted e.g. Site Master File schematics
- Review close-out commitments from previous TGA inspection. Is CAPA complete and effective?
- Ensure documentation, quality incident reports, PQS, validation, qualification, BMR/BPR documentation, and related quality records will be available for review

Inspection process

- Preparation
- Conduct
- Post inspection and closure

During inspection we examine:

- Personnel & training
- Documentation
- **Quality System** deviations, change controls, complaints, risk assessments, annual product reviews, recalls, selfinspections, returned goods, hygiene and gowning, technical agreements, supplier approval, rework, reprocessing, stability program, technical agreements
- Production processes
- Facility/Engineering calibration and maintenance
- Utilities HVAC, water systems, compressed air, gases
- Validation and Qualification
- Quality Control activities and records
- Batch records

Documentation

- QA systems
- Production
- QC
- Validations/Qualifications
- Documentation revision & distribution
- Registers and logs available & in use
- System for document revisions and obsoletion
- Batch document design, issuance, control
- Clear procedures available in agreed format
- Good documentation practices adhered to

- Documentation
- QA systems
- Production
- Quality Control
- Validations/Qualifications
- Product quality reviews & grouping strategies
- Product release
- Management reviews & resourcing
- Training & its effectiveness
- Control of quality incidents
- Risk management
- Change management
- Control of materials & supplier approval
- Outsourced activities

- Documentation
- QA systems

Production

- Quality Control
- Validations/Qualifications

- Warehousing processes & monitoring
- Control of materials
- Facilities and equipment
- Manufacturing & packaging instructions
- Manufacturing & packaging processes & cleaning
- Process monitoring & records
- Environmental controls & monitoring
- Calibration & maintenance of equipment
- Cross contamination control strategies
 - o People/ Environment
 - o Equipment
 - o Process

- Documentation
- Investigations/QA systems
- Production
- Quality Control
- Validations/Qualifications

- Suitably skilled staff
- Equipment & instrumentation use, calibration & maintenance
- Sampling program and processes
- Sample management
- Standards & reagent management
- Test methods & their validation
- Laboratory investigations
- Records & data management
- Computerised systems admin & use

- Documentation
- QA systems
- Production
- Quality Control
- Validations

- Validation master plan
- Planning of validation & qualification activities
- URS, DQ, IQ, OQ, PQ processes formalised
- Utility qualifications
- Equipment qualifications
- Process validations
- Cleaning validation
- Computerised system verification / validation
- Revalidation program

W N

Expectation during inspection

The inspector

- Honest, open and respectful
- Empathetic
- Encourage and allow staff time to respond
- Be patient and allow time to evaluate manufacturer's responses
- Respectfully evaluate feedback to any issue raised and engage in reasoned discussion
- Provide a daily summary of points to avoid any surprises
- Leave site with a summary of all observations

Expectations during inspection

Manufacturer representatives

- Honest, open and respectful
- No delaying tactics
- Respond to questions and provide evidence
- Have your SMEs available,
- Have support staff ready to retrieve documents
- Have planned activities for the inspector to observe at the time of inspection (where possible)
- Help the inspector to execute the inspection plan while in each area
- Provide accurate site schematics as requested

Expectation at Inspection

Manufacturer representatives

- Use scientific expertise to justify points
- Be truthful
- Be aware of your body language (consistency with words said)
- Words to avoid: I think, I'm not sure, In my opinion, As I recall, Honestly, Usually, Typically, don't remember,...
- Phrases to avoid :
 - That's the way we've always done it.
 - Off the record,.....
 - I shouldn't say this but.....

Post Inspection

Classification of Deficiencies

Deficiency	Few examples for illustration
CRITICAL	Lack of sterilisation validation Intentional falsification or misrepresentation of test results or records Inadequate segregation
MAJOR	Lack of appropriate validation Cleaning program not followed Grossly inadequate or no air filtration
OTHER	GMP issue, but not classified as a critical or major issue. A single hand amendment to a procedure A single missing signature on a document

Inspection process

- Preparation
- Conduct
- Post inspection and closure

- Post inspection letter (PIL) listing deficiencies is prepared, peer reviewed & issued
- Manufacturer has 4 weeks for 1st response, 2 weeks for 2nd and 3rd response (if required) until satisfactory response received*
- Once closed, the final inspection report is issued
 - o compliance rating determined
 - o indication of reinspection timing- based on product risk and compliance rating

*If the inspection cannot be closed in 3 responses it is escalated to a review panel with involvement of TGA compliance group

Post Inspection and Closure

Responding to deficiencies

- Manufacturer provides responses to the deficiencies.
 Details include how issues will be corrected + timeframes for completion
- Inspector reviews responses
 - o Accepts or rejects proposed corrective actions
 - Can request additional information or clarification
- Three attempts to provide an acceptable response to all issues
- Following receipt of acceptable responses, an inspection report will be issued
- The report will contain both good practices and areas for
- improvement seen at inspection

Responding to the Post Inspection Letter (PIL)

Provide focused responses to reported deficiencies

- Focus on demonstrating compliance with the requirements as recorded in the close out record
- Conduct root cause analysis for critical & major issues
- Risk identifications & assess impacts
- Clearly document corrective actions
- Provide suitable & achievable CAPA completion date

If the response was not accepted

- Identify why and seek clarification if required
- Carefully respond to inspector's comments
- Respond comprehensively to avoid further responses
- Provide focused response/s

Expectation of inspector during close out

REVIEW	 Allocate suitable time for review & prioritize provision of feedback Assess manufacturer's response considering issues identified Assess timing of completion of CAPA
PROVIDE FEEDBACK	 Identified gaps in information or request justifications as needed to ensure issues fully resolved Provide guidance or clarification to the manufacturer to facilitate/target subsequent responses

After the Inspection Close-out

TGA risk based re-inspection frequency

Number of deficiencies	0 major & < 10 ot	her		1-5 major & < 20 other	6-10 major & < 30	> 10 major & Any critical		
Risk category	3 rd consecutive A1	2 nd consecutive A1	1 st A1	A2	1 st A3	Repeat A3	Unacceptable	
HIGH	Sterile medicines, primary packaging of sterile medicines, non-sterile medicines containing potent actives (antibiotics, steroids, hormones antineoplastics), biotechnology APIs, sterile APIs for aseptic use & single step sterilisers							
Months to re- inspection	36 + possible reduced scope	36	24	18	12	Compliance management	Compliance management	
MEDIUM	Registered non-sterile medicines (including registered herbal) & other APIs for use with sterile preparations that undergo a subsequent sterilisation step (filtration or terminal sterilisation) and not included in the high risk category							
Months to re- inspection	36 + possible reduced scope	36	30	20	15	Compliance management	Compliance management	
LOW	Sunscreens, medicinal gases, non-sterile APIs for registered medicines & single manufacturing steps such as analysis & testing, labelling, secondary packaging, release for supply & storage							
Months to re- inspection	36 + possible reduced scope	36 + possible reduced scope	36	24	18	Compliance management	Compliance management	
LOW - LISTED	Listed medicines							
Months to re- inspection	48 + possible reduced scope	48	42	30	18	12	Compliance management	
Risk Based Approach to Inspection Frequency – TGA Forum June 2018								

How to ensure GMP inspection success

- Maintain knowledge of current GMP requirements, TGOs & guidance documents
- Follow your own procedures confidently
- Make procedures clear, concise and easy to follow
- Consistently investigate quality incidents. Determine root cause using scientific principals. Implement meaningful CAPA
- Ensure core elements of the Code are applied consistently
- Confidently involve staff in the inspection process without reservations
- Ensure staff undergo regular training. Meaningful evaluate training effectiveness
- Always looking for ways to improve or upgrade over time

How to ensure GMP inspection success

- Trust staff in their areas of expertise to be involved in decision making
- Respond clearly to the inspector's questions
 - Multiple different answers create doubts
 - Provide additional information in a timely manner
- Awareness of inspector's next question or review topic
 - Being proactive and ready shows confidence
- Keep track of inspector's requests & provide updates if delays
- Have a comprehensive self-inspection process

Case 1: Dispensing

A manufacturer has dispensing conducted for multiple products in one dispensing area.

Materials dispensed included an antibiotic that was allergenic, very low-density and high potency.

Dispensing performed in campaign.

Information provided at inspection:

- Dedicated dispensing tools in use
- HVAC system last qualification 2017
- The HVAC system is shared with blending/mixing rooms
- One cleaning protocol applied to all
- Cleaning validation conducted for allergenic materials only (no justification recorded)

Potential cross contamination issues

- One cleaning protocol not validated for all materials or scientifically assessed for effectiveness
- High risk materials, low density, allergenic and high potency dispensed in one area
- Effectiveness of the HVAC system operation not regularly confirmed

Case 1: Dispensing

If separate dispensing was not an option

- Effective risk assessment showing mitigation and measures to minimise cross contamination
 - Revalidation of the HVAC system more frequently
 - Pressure differential monitoring
 - HVAC system dedication, or use of LAF
 - Personnel gowning
- Specific cleaning protocols for high- risk materials including validation
- Periodic revalidation to confirm continuous control

Case 2: Non-conformance & OOS investigation

Laboratory analysis identified OOS in dual active tablet product

- Active A was 86% (spec. 95 -105%)
- Active B was 98% (spec. 95 -105%)

The same analytical method was used to analyse both actives.

The laboratory investigated and reported:

- No lab error and no root cause in the lab could be found
- The laboratory resampled and retested and results were A: 97.0% & 96.3%. No results recorded for Drug B
- The laboratory accepted the new result for Active A and released the batch

Issues

- Failure to risk assess and determine potential root cause/s to
 - o Justify repeat testing
 - Facilitate corrective actions to eliminate repeat occurrence
- Failure to include active B in retest and include in the assessment
- Insufficient information obtained to justify invalidating original OOS result

Case 3: Change Control

New product introduction at a contract manufacturer.

Product active was highly viscous. The new active ingredient had NOT previously been used before in site operations.

A change control was raised. Product was accepted and contract approved based on:

- Similar product already manufactured at site, however, it did not include a viscous active material
- Supplier was approved for supply of other materials
- The risk assessment for new product evaluated it as low risk
- 2 trial batches to justify process validation

Issues /system failures

- Similar product contracted, does not mean new product with new material would be the same
- Supplier approval did not evaluate the new material
- The risk assessment for new product introduction failed to assess cleaning validation with new material, or cross contamination impact in manufacturing
- No scientific justification for 2 trial batches for process validation
- No evaluation of impact of material usage or handling

REMEMBER: Key points to ensure inspection success

Understanding of the GMP Code TGO's & guidance documents Apply them effectively Effective Design and application of the PQS system Regular Quality Reviews Understand Operation Identify, mitigate, control or eliminate risks to product quality

Validation& Qualification Revalidation reviews Quality Control /Quality Assurance expertise Effective investigations to root cause/effective CAPAs

Effective self inspection program including for post release

Summary

- GMP inspections
- Inspection coverage
- Inspection preparation and process
- Expectation at Inspection
- Effective close out
- Case studies

Questions?

Scan this QR code with your device to submit a question

GMP FORUM 2024

Australian Government

Department of Health and Aged Care Therapeutic Goods Administration